GlassScriptPhysician profile
Karmila C Murphy
NPI 1184234783
$5,823.35
in general payments reported to CMS, 2019-2025
24 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $841 · 2022: $694 · 2023: $806 · 2024: $2,093 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179 · Consulting Fee: $796 · Education: $285 · Travel and Lodging: $28.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,179.05 |
| Consulting Fee | $796.25 |
| Education | $285.21 |
| Travel and Lodging | $28.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $996.75 | 2024-2025 | Epkinly |
| Janssen Biotech, INC. | $825.96 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Adc Therapeutics America, INC. | $600.66 | 2022-2025 | |
| Incyte Corporation | $536.93 | 2021-2025 | Monjuvi |
| Seagen INC. | $447.19 | 2022-2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $337.77 | 2024-2025 | Calquence |
| Karyopharm Therapeutics INC. | $295.65 | 2021-2025 | Xpovio |
| Pfizer INC. | $266.33 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $261.02 | 2021-2022 | |
| Abbvie INC. | $225.28 | 2023-2025 | |
| Lilly USA, LLC | $168.01 | 2023-2025 | Jaypirca |
| Amgen INC. | $162.28 | 2021-2023 | Xgeva |
| Beigene USA, INC. | $124.98 | 2023 | Brukinsa |
| Genentech, INC. | $123.12 | 2025 | Tecentriq |
| Celgene Corporation | $92.05 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $90.18 | 2021 | |
| Genzyme Corporation | $67.46 | 2023-2024 | |
| Sobi, INC | $34.20 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $33.37 | 2024 | Tazverik |
| Pharmaessentia USA Corporation | $31.73 | 2023 | Besremi |
| Glaxosmithkline, LLC. | $29.88 | 2025 | Blenrep, Ojjaara |
| Adaptive Biotechnologies Corporation | $24.78 | 2025 | Clonoseq |
| Morphosys, US INC. | $24.75 | 2021 | |
| Kyowa Kirin, INC. | $23.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karmila Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.